Isoflavones found in soy products can help reduce the risk of developing early prostate cancer in men who have consumed soy their entire lives but might also increase the risk of advanced prostate cancer.
Abbott Laboratories and Japan's Astellas Pharma filed suit to prevent the FDA from allowing Ranbaxy Laboratories Ltd., Teva Pharmaceutical Industries Ltd. and Novartis AG's Sandoz unit to market a generic version of the antibiotic Omnicef. The treatment for ear, sinus, throat and skin infections had $637 million in sales last year for Abbott, which claims the Omnicef patent is good until 2011.
A group of researchers in Denmark have discovered two enzymes they say can convert any donated blood to group O, the only type that is safe for everyone. The Elizabethkingia meningosepticum gut bacterium, a cause of opportunistic infections, targets the A antigen, and Bacteroides fragilis removes the B antigen. The researchers say the purified enzymes are very efficient and they plan to work with a company in Massachusetts to plan clinical trials.
The FDA approved Merck's diabetes treatment Janumet, a combination of its diabetes drug Januvia, which was approved just last year, and the older drug metformin. Janumet is the first pill to treat Type 2 diabetes by targeting all causes of the disease. Analysts expect Janumet and Januvia to bring in more than $2 billion in annual sales for Merck.
Japanese researchers report patients who took high doses of fish oil along with statins had fewer heart problems than those who took drugs alone. A long-term intake of fish oil plus statins helped reduce the death risk for high-cholesterol subjects by 19% compared with patients on drugs alone, the study showed.
Cephalon said the FDA intends to approve its narcolepsy drug Nuvigil but requires a label warning about possible skin rash and hypersensitivity. The FDA's approvable letter also asked Cephalon for a standard safety update from clinical trials and information on promotional materials.